The specific B-cell depleting anti-CD20 monoclonal antibody rituximab (RTX) is effective in terms of the treatment of various immune-mediated glomerulopathies. The administration of RTX has been shown to be reliable and highly effective particularly in patients with ANCA-associated vasculitis. which is manifested predominantly with non-nephrotic proteinuria. Stable long-term B-cell de... https://www.spidertattooz.com/